Glaukos Corp

GKOS

Company Profile

  • Business description

    Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

  • Contact

    One Glaukos Way
    Aliso ViejoCA92656
    USA

    T: +1 949 367-9600

    E: [email protected]

    https://www.glaukos.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2025

    Employees

    995

Stocks News & Analysis

stocks

Undervalued ASX founder-led companies

Can this strategy pick the winners?
stocks

AI stocks post big gains in Q3. These are the winners and losers

Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks

12 picks for an income portfolio - Q3 2025 update

Fifteen months in and passive income growth has exceeded my target.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,253.6025.70-0.28%
CAC 407,941.8029.98-0.38%
DAX 4024,332.6845.61-0.19%
Dow JONES (US)46,694.9763.31-0.14%
FTSE 1009,491.1712.030.13%
HKSE26,957.77183.15-0.67%
NASDAQ22,941.67161.160.71%
Nikkei 22547,950.886.120.01%
NZX 50 Index13,531.2942.050.31%
S&P 5006,740.2824.490.36%
S&P/ASX 2008,956.8019.10-0.21%
SSE Composite Index3,882.7820.250.52%

Market Movers